LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genomics Data Analysis System Speeds Drug R&D

By LabMedica International staff writers
Posted on 25 Nov 2009
Print article
A new genomics data-analysis system was designed for advancing life science research, discovery, and development.

Tibco Software, Inc. (Palo Alto,CA, USA), together with Integromics (Madrid, MA, USA), a provider of software systems for data management and data analysis in genomics, proteomics, and drug discovery, reported that Integromics Biomarker Discovery 2.0 for Tibco Spotfire is a new solution that sets the standard for advanced methods of data access, normalization, pattern detection, treatment comparison, and functional analysis for scientists analyzing genomic expression data. This powerful platform plays a pivotal role in leveraging the considerable investment in gene expression technologies that the pharmaceutical and biotechnology industries have made in the last 10 years. Gaining new insights into disease biology, mechanism of action and drug safety will be a key differentiator in early drug discovery.

The scientific and workflow knowledge of Integromics--combined with the adaptability and ease of use of the Tibco Spotfire enterprise analytics platform--provides pharmaceutical, biotechnology, and academic research groups a powerful genomic data analysis environment that rapidly finds and categorizes complex patterns. With interactive analysis and high-impact visualization capabilities, Integromics Biomarker Discovery 2.0 for Tibco Spotfire quickly reveals insights and unexpected relationships in genomics data. This allows researchers and scientists to examine the expression and annotation dimensions of their data and perform a variety of numerical analyses--all in one application. Pharmaceutical companies can also use Tibco Spotfire as a flexible analytics platform to combine and analyze new types of data to pursue more quickly hypotheses and research strategies.

"Having developed microarray analytics for over five years and benefited from a successful partnership with Spotfire for several years now, we are confident that this combined solution will provide researchers with a powerful environment to accelerate discovery and provide accurate, up-to-date analytics from a single reliable source,” said Imad Yassin, global commercial director, Integromics. "With this set of tools, life-science researchers can ask and answer new questions and create an advanced problem solving environment.”

"Genomics research typically involves measuring the activity of thousands of genes in many different treatments or conditions, and combining that information with other data to uncover new insight into the biology of disease and treatment,” said Mark Lorion, vice president of marketing, Tibco Spotfire. "This solution helps researchers and scientists address one of the industry's long-standing challenges of creating knowledge from mass data by easily integrating multiple data sources and transforming data into an interactive decision-making asset.”

Integromics develops information technology (IT) solutions for life sciences (genomics and proteomics) in two strategic areas: data management/integration and intelligent data analysis. Over the years, the company has developed a network of collaborations and partnerships with leading industry and academic organizations to provide complete technological solutions that enable scientists to make new discoveries from their research data. Integromics operates globally in Asia Pacific, Europe, and the United States.

Tibco Software is a leading provider of enterprise analytics software for next generation business intelligence. Distinguished by its speed to insight and adaptability to specific business challenges, Spotfire rapidly reveals unseen threats and new opportunities, creating significant economic value.

Related Links:

Tibco Software
Integromics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more